KORRO BIO INC (KRRO)

KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024

KRRO stock results show that Korro Bio beat analyst estimates for earnings per share the first quarter of 2024.

KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Korro Bio (NASDAQ:KRRO) just reported results for the first quarter of 2024.Kor...

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second...

Korro Bio is Now Oversold (KRRO)

Korro Announces $70 Million Private Placement

Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236...

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President,...

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of...

BMO starts Korro at outperform, cites upcoming data for AATD drug (NASDAQ:KRRO)

BMO initiated coverage of Korro Bio (KRRO) with an outperform rating, citing upcoming data for its AATD drug candidate KRRO-110 and potential partnerships. Read more here.

These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?

These stocks are coming off a banner month, but what about the road ahead?